Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.
about
Chemotherapy with platinum compounds for metastatic colorectal cancerThe changing face of chemotherapy in colorectal cancerFactors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patientsTernary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell linesOxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancerProtracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors.Oxaliplatin with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFOX 4) as first-line therapy for patients with metastatic colorectal cancer.A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.Management of stage IV rectal cancer: palliative options.An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report.Two-stage strategy for patients with extensive bilateral colorectal liver metastases.Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways.Systemic chemotherapy of liver tumors.Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.Recent and ongoing clinical trials for treating colorectal cancer.New treatments with curative intent for metastatic colorectal liver cancer.Metastatic colorectal cancer: systemic treatment in the new millennium.Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer.Survival of untreated advanced colorectal cancer patients.Development and progression of colorectal neoplasia.Oxaliplatin (L-OHP): a new reality in colorectal cancer.Ongoing and unsaid on oxaliplatin: the hopeOxaliplatin in practiceOxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis.Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancer.Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon CancersPrognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderlyHypersensitivity reactions related to oxaliplatin (OHP).Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancerPhase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical TrialRole of oxaliplatin in the treatment of colorectal cancerOxaliplatin-based chemotherapy in the management of colorectal cancer.Oxaliplatin/5-FU without leucovorin chemotherapy in metastatic colorectal cancer.XELOX in colorectal cancer: a convenient option for the future?
P2860
Q24250512-C5213A70-C75C-4D0E-99CD-41DDD8644FE9Q28345461-F692D391-5777-4CBD-B8A2-85AE06B3EBC8Q28346039-FCFAEDA6-8ADE-4262-A7F9-1F5180E9CD97Q28350941-F45FE955-A016-4044-848C-0C19E023768AQ28364999-5FAC9F7A-61FC-4311-838F-CF55D74F43D2Q33357849-45E2339E-B42E-4F89-A21A-17C6097C8B83Q33366782-98CA6A21-0444-4F4F-B4C2-28585624272CQ33368773-B463CE88-D554-49A3-A18F-A75DBBE6C73CQ33389165-E6D9F514-8D40-4CEF-BBC1-FFCB6BDA1579Q33746097-6D11E70E-FD32-4C20-9620-46B53BEE2FA3Q33849034-AFB836B8-6D96-496B-B6E6-93ADF5DE1AFBQ33863103-03F81DF9-1A0A-4EDB-B0DD-8832059AA43EQ33865026-3CCF7FBD-D73E-466C-9362-E8DAA7261E65Q33934922-E3EEAD26-2E18-48F6-9F12-735F8CB235FBQ34110952-416961DA-D565-471C-9111-4A8D7E7EB9BCQ34342186-11466B2D-BA5A-4E85-92B5-341D63CE78AFQ34349053-38FEA160-5A92-479B-A6E2-794035DFA303Q34660903-9F6E9B5D-4987-4BC7-852B-7CE247A5C106Q34768529-99C5F86A-CC51-4679-B564-7E6E94116F68Q35148795-A6ECA60A-6FFC-42CD-9673-A3A9C5F9545BQ35340865-3C7B9D09-C1F5-4BB9-8AA5-2AF05FBCF3A4Q36120932-A9DCA517-E656-489A-B4F7-3AE9A1512322Q36241935-1BF3527C-7919-45D3-81D8-CD5CF8091322Q36291590-30B91A74-8B6E-4388-B502-E07E05AE2541Q36291594-39517843-EA46-476F-BBB9-3FA2CF4E8339Q36291603-91093D93-FA14-4D91-ADB1-1A1045DD53BFQ36316717-F2C9F9DA-0C80-419C-8C64-8E0024B5A8E4Q36391430-D14E155F-7B15-4684-B83B-71988E851D01Q36487348-9E0371EA-19DF-4B2A-AB6D-1851B6B84FDEQ36642224-632604D8-2887-46C5-938A-8B2DF883DD35Q36671275-283D0B86-9195-4DDA-81F0-F4B4FFD3AF0CQ36671350-FEAACC6D-D944-4E0F-838D-DC6D14D5EEAFQ36671812-654A7EA2-B775-4D48-AA42-72A7C274A7A4Q36677787-78F8031A-B862-46DB-A8D5-374C3B09AA2AQ36695083-2EDD753D-2800-4201-8190-BF6F17EA03B9Q36848090-DB31E20B-4BE5-4597-99B5-3A1833C91C14Q37230238-311BC20B-DA90-4F71-B3AE-51C7A6ED8643Q37242664-C272D804-E221-49E1-8809-B1CFA9754E89Q37449141-39D3B127-245B-402D-888D-5BF969C677BAQ37839084-81C2E633-8302-4C1E-9AD9-7AC8BB391887
P2860
Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.
description
1997 nî lūn-bûn
@nan
1997 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Oxaliplatin with high-dose leu ...... metastatic colorectal cancer.
@ast
Oxaliplatin with high-dose leu ...... metastatic colorectal cancer.
@en
type
label
Oxaliplatin with high-dose leu ...... metastatic colorectal cancer.
@ast
Oxaliplatin with high-dose leu ...... metastatic colorectal cancer.
@en
prefLabel
Oxaliplatin with high-dose leu ...... metastatic colorectal cancer.
@ast
Oxaliplatin with high-dose leu ...... metastatic colorectal cancer.
@en
P2093
P1476
Oxaliplatin with high-dose leu ...... metastatic colorectal cancer.
@en
P2093
Tournigand C
de Gramont A
P304
P356
10.1016/S0959-8049(96)00370-X
P577
1997-02-01T00:00:00Z